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Risk factors for severe COVID‑19
differ by age for hospitalized adults
Sevda Molani1,8, Patricia V. Hernandez1,2,8, Ryan T. Roper1, Venkata R. Duvvuri1,
Andrew M. Baumgartner1, Jason D. Goldman3,4,5, Nilüfer Ertekin‑Taner6, Cory C. Funk1,
Nathan D. Price1,7, Noa Rappaport1 & Jennifer J. Hadlock1*
Risk stratification for hospitalized adults with COVID-19 is essential to inform decisions about
individual patients and allocation of resources. So far, risk models for severe COVID outcomes have
included age but have not been optimized to best serve the needs of either older or younger adults.
Models also need to be updated to reflect improvements in COVID-19 treatments. This retrospective
study analyzed data from 6906 hospitalized adults with COVID-19 from a community health system
across five states in the western United States. Risk models were developed to predict mechanical
ventilation illness or death across one to 56 days of hospitalization, using clinical data available within
the first hour after either admission with COVID-19 or a first positive SARS-CoV-2 test. For the sevenday interval, models for age ≥ 18 and < 50 years reached AUROC 0.81 (95% CI 0.71–0.91) and models for
age ≥ 50 years reached AUROC 0.82 (95% CI 0.77–0.86). Models revealed differences in the statistical
significance and relative predictive value of risk factors between older and younger patients including
age, BMI, vital signs, and laboratory results. In addition, for hospitalized patients, sex and chronic
comorbidities had lower predictive value than vital signs and laboratory results.
The number of global confirmed cases with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2)
infection has surpassed 257 million as of December 10, 2021, with over 5 million reported deaths1. Although
the majority of patients infected by SARS-CoV-2 present with mild symptoms, studies reported that 20% get
hospitalized and 5% of patients with Coronavirus disease 2019 (COVID-19) become critically ill2,3. From early
on of the pandemic, both age and chronic comorbidities have been reported as a significant risk factor for poor
outcomes4,5, and evidence supports increased risk with hypertension, diabetes, chronic obstructive pulmonary
disease, chronic renal disease, and cardiovascular c onditions4,6,7. Although young patients have a lower prevalence
of comorbidities than aging patients, the relative risk of fatal outcome in young patients with hypertension, diabetes and cardiovascular diseases has been shown to be higher than in elderly patients8,9. In addition, some studies
show the patient population tends to be younger with the emergence of delta as the variant of concern in the U.S.
with regional proportions being greater than 99% as of November 2 02110. Assessing risk for severe COVID-19 in
specific age groups is complicated by both the heterogeneity of clinical presentation and age-related differences
in the prevalence of chronic multimorbidities. A deeper understanding of risk factors for COVID-19 severity
among different age subpopulations is needed, as well as practical, explainable risk stratification for bedside
clinical decision support, research stewardship, and advancing our biomedical understanding of SARS-CoV-2.
Several studies have described successful development of machine learning models to predict COVID-19
outcomes in hospitalized patients11–20. Further, explainable models can also inform care decisions by showing
which factors lead a specific individual patient to be at risk for severe outcomes, and can also help show which
variables are most important at the population level, suggesting areas for further research i nvestigation21. However, existing studies have several limitations; (1) most are based on small sample sizes from academic centers, (2)
higher incidence of severe outcomes in hospitalized cohorts than are typically observed with current treatments,
(3) reliance on laboratory tests that are not routinely administered to all patients, (4) lack of investigation of differences in risk factors between younger and older hospitalized patients, and (5) marginal model performance
for either of age groups13. To address these limitations, we develop high-performing age-stratified machinelearning models to predict the severity of COVID-19 progression from 6,906 patients in community hospitals
across a large geographic area in the western United States, during five months after the delta variant had become
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predominant and new standards of care had lowered the severe outcome incidence rate. In addition, the model
was developed to require only those laboratory results that are routinely administered for all COVID-19 patients.

Methods

Study design and setting. This retrospective study analyzed data gathered from Providence St. Joseph
Health (PSJH), a community health system with 51 hospitals and 1085 clinics across five states in the western
United States: Alaska, California, Montana, Oregon, and Washington. Inclusion criteria was age ≥ 18 years and
confirmation of COVID-19 by a positive PCR-based SARS-CoV-2 test result. This study was performed in compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule and was approved
by the Institutional Review Board (IRB) at PSJH with Study Number STUDY2020000196 with waiver of consent.
We follow STROBE reporting guidelines (Supplemental Table S6).
Task definition. In this study, we hypothesized that age-stratified risk models for hospitalized patients with

COVID-19 can accurately predict critical illness and mortality due to COVID-19 based on readily available
patient data. Outcomes of patients were defined using the World Health Organization Ordinal Scale (WOS),
proposed by the WHO R&D Blueprint group in their COVID-19 Therapeutic Trial S ynopsis22. The WHO ordinal scale ranges from 0 (uninfected) to 8 (deceased) with gradations depending on hospitalization, supplemental
oxygen, mechanical ventilation, and organ support (vasopressors, renal replacement therapy, and extracorporeal
membrane oxygenation). See Supplemental Table S1. In this study, we categorized WHO ordinal scores of 3–5
as the mild cases of COVID-19 and WHO ordinal scores of 6–8 as the critical illness and death within hospitalized patients. The objective is to develop machine learning models to predict critical illness and death with
COVID-19 in hospitalized patients using easily available variables, including aggregated laboratory biomarkers
and vital signs within one hour of either admission to the hospital or the first positive inpatient SARS-CoV-2
test. These predictive models are developed on time horizons for one, seven, 14, 28, and 56 days from the confirmation of the infection and hospitalization to test the assumption that the baseline data up to one hour after
hospital admission with a positive SARS-CoV-2 test can predict risk of critical illness on different time horizons.
Additionally, we compare the performance of machine learning models within 7-days from the confirmation of
the infection and hospitalization for (1) all-ages population, and (2) age-stratified subpopulations, to report the
effect of age and compare the relative importance of risk factors between younger and aging adults.

Population. The start time point of study is defined as June 31, 2021, after the delta became the predominant
SARS-CoV-2 variant in the Western United States. Studied population included hospitalized individuals who
received a positive test for COVID-19 between June 31, 2021 and November 15, 2021. This was confirmed by
reverse-transcriptase polymerase chain reaction (RT-PCR) for the SARS-CoV-2 ribonucleic acid (RNA). Patients
were excluded if they were already receiving mechanical ventilation at the time of admission to the hospital.
Variables. The factors analyzed for prediction of COVID-19 outcomes were demographic characteristics,

medical history, vital signs, and laboratory biomarkers (n = 64). We extracted the Charlson Comorbidity I ndex23
(CCI: measure of overall comorbidities) and individual chronic conditions that are known risk factors for poor
COVID-19 outcomes (reported in the literature6) and conditions which are prevalent in aging patients (Table 1).
Comorbidities that are usually chronic, such as hypertension, were included if they were active at the time of
admission. Other comorbidities were included if they had been active any time within 2 years prior to admission, except for malignancy, which was included if active any time within the past 5 years. Note that active
conditions mean health issues that affect the individual’s current functioning and all health. We used ICD10-CM (International Classification of Diseases, Tenth Revision, Clinical Modification) codes, which are shown
together with SNOMED–CT© hierarchical parent codes (Supplemental Table S2). Laboratory results and vital
signs were included (both inpatient and outpatient) if they were collected between 24 h before and one hour
after either admission to the hospital or the first positive inpatient SARS-CoV-2 test (Table 1). Note that, we used
aggregated temporal longitudinal vital signs in our model as described in Lee, et.al24. Additionally, the risk factor
list included patients’ need for supplemental oxygen mode, need for vasopressors, total number of comorbidities,
and COVID-19 vaccination status.

Statistical analysis. Descriptive analyses are presented as frequencies and percentage for categorical vari-

ables, and as mean and standard deviation (std) for numerical variables. Fisher exact test was applied to compare
distributions of categorical variables. The differences between distributions of numerical variables were calculated using Mann Whitney U-test. All statistical analyses were completed using PySpark version 2.4.5.

Risk model development. In data preprocessing for development of each risk model, we removed features
with missing values greater than 20% (Supplemental Table S3). We used IterativeImputer from Scikit Learn version 0.24.0 for imputing missing data in numerical features25. Missing values for comorbidities were assumed to
be absent from the patient’s medical history and imputed with a constant number of 0. Outliers were detected
by calculating the modified z-score based on median absolute deviation with a threshold of 3.5 and then these
outliers were imputed by the median.
To build machine learning models, we randomly split the dataset into 80% training data and 20% testing
data and analyzed each patient using multiple algorithms including logistic regression (LR), random forest classification (RF), Adaptive Boosting (AdaBoost), and Gradient Boosting Decision Tree (GBDT). The parameters
for each model were optimized using a tenfold cross-validation on the training set with the maximum scoring
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Demographics

Vital signs

Laboratory tests

Medical conditions

Other risk factors

Age

Heart rate (HR)

White blood cell count (WBC)

Hypertension

Initial oxygen mode

Body mass index (BMI)

Respiratory rate (RR)

Platelets (PLT)

Coronary arteriosclerosis

Total Number of comorbidities

Sex

Systolic blood pressure (SBP)

Hematocrit (HCT)

Heart failure

Vaccination status

Reported ethnicity

Diastolic blood pressure (DBP)

Hemoglobin (HGT)

Cardiomyopathy

Vasopressors

Temperature

Basophils (BASO)

Chronic obstructive pulmonary disease
(COPD)

Oxygen saturation (SpO2)

Eosinophils (EOSABS)

Asthma

Lymphocytes (LYMABS)

Malignancy

Monocytes (MONO)

Liver disease

Neutrophils (NEUABS)

Hyperlipidemia and Dyslipidemia

Potassium (K)

Obstructive sleep apnea

Sodium (NA)

Chronic kidney disease

Chloride (CI)

Diabetes mellitus

Bicarbonate (HCO3)

Solid organ transplant

Creatinine (CREA)

Conditions related to reduced immune
response

Blood urea nitrogen (BUN)

Dementia (All Causes)

Reported race

Glucose (GLU)
Albumin (ALB)
Alkaline (ALP)
Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)
Anion Gap (AGAP)
Bilirubin (TBIL)
Calcium (CA)
Globulin (GLOB)
Total Protein
D-dimer
C-reactive protein
Prothrombin time
BUN/Creatinine Ratio
Ferritin
International normalized ratio (INR)
Magnesium (MG)
Procalcitonin
Lactate dehydrogenase (LDH)

Table 1.  Demographics, vital signs, laboratory tests, and medical conditions analyzed for SARS-CoV-2
positive patients.

value for the area under receiver operating characteristic curve score (AUROC). We then balanced true and false
positive rates by optimizing the probability threshold for each class. This optimal cut-off point is defined using
the Youden index to maximize the summation of true positive rate and true negative rate.
To address collinearity between predictors, we compared the optimum performance of logistic regression
using the least absolute shrinkage and selection operator (LASSO) feature selection method. For non-linear
tree-based models all features were included. Performance of models was reported as the area under the receiver
operating characteristic curve (AUROC), area under the precision-recall curve (AUPRC), true positive rate
(TPR), true negative rate (TNR), predictive positive value (PPV), and negative predictive value (NPV). We
reported the 95% confidence interval for performance metrics of the models using Wilcoxon statistics26, and
binomial interval27 for the area under the ROC and precision-recall curves, respectively. All ML models were
applied using Spark version 2.4.5, in the Python interface. We presented the interpretation of the model with
the highest relative performance, gradient boosting, using the Shapley additive explanations (SHAP) algorithm,
which uses cooperative game theory to calculate the marginal contribution of each feature, and examines the
feature influence on model p
 rediction28. Predictive models were reported following TRIPOD guidelines29.

Results

Baseline characteristics. In the Providence St Joseph cohort (described in “Methods” above), 6,906
patients with positive tests for SARS-CoV-2 were analyzed (Supplemental Fig. S1). The severe outcome incidence
rate of 10.88%. Percent female was 44.25 and mean age was 59.90 years (SD ± 17.83 years), with a range 18 to
90 + years old. The distribution of relative frequency of hospitalizations by age is shown in Supplemental Fig. S2.
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Patients with age ≥ 18 and < 50 years (n = 1,963)

Patients with age ≥ 50 years (n = 4,943)

Variable

Mild (WOS ≤ 5)
(n = 1,810)

Severe (WOS > 5)
(n = 153)

P-value

OR*

Mild (WOS ≤ 5)
(n = 4,349)

Severe (WOS > 5)
(n = 595)

P-value

Age in years, mean (std)

37.21 (8.27)

39.320 (8.15)

< 0.001

-

68.67 (11.63)

70.17 (11.64)

< 0.001

-

BMI, kg/m2, mean (std)

34.18 (9.46)

37.219 (1.00)

< 0.001

-

31.06 (8.31)

32.10 (9.10)

< 0.001

-

Sex (Male)

991 (54.75%)

92 (60.13%)

0.205

1.246

2367 (54.43%)

356 (59.83%)

0.014

1.247

Ethnic group (Hispanic)

565 (31.21%)

53 (34.64%)

0.415

1.168

537 (12.35%)

74 (12.44%)

0.947

1.008

Race**

742 (40.99%)

64 (41.83%)

0.864

1.035

1006 (23.13%)

152 (25.55%)

0.197

1.140

Hypertension

95 (5.25%)

6 (3.92%)

0.571

0.737

863 (19.84%)

111 (18.65%)

0.510

0.926

Coronary Arteriosclerosis

11 (0.61%)

2 (1.31%)

0.269

2.166

429 (9.86%)

50 (8.40%)

0.301

0.838

Heart failure

26 (1.44%)

6 (3.92%)

0.034

2.801

471 (10.83%)

68 (11.43%)

0.674

1.062

Cardiomyopathy

9 (0.50%)

3 (1.96%)

0.061

4.002

112 (2.57%)

13 (2.18%)

0.676

0.845

COPD

6 (0.33%)

1 (0.65%)

0.434

1.978

390 (8.97%)

46 (7.73%)

0.355

0.851

Asthma

82 (4.53%)

6 (3.92%)

1.000

0.860

226 (5.20%)

27 (4.54%)

0.552

0.867

Malignancy

39 (2.15%)

4 (2.61%)

0.573

1.219

412 (9.47%)

50 (8.40%)

0.453

0.877

Liver disease

71 (3.92%)

7 (4.57%)

0.665

1.174

232 (5.33%)

32 (5.38%)

0.923

1.009

Dyslipidemia, Hyperlipidemia

122 (6.74%)

14 (9.15%)

0.247

1.394

1188 (27.32%)

150 (25.21%)

0.302

0.897

Obstructive sleep apnea

52 (2.87%)

6 (3.92%)

0.452

1.380

347 (7.98%)

37 (6.22%)

0.142

0.765

Chronic kidney disease

27 (1.49%)

4 (2.61%)

0.298

1.773

523 (12.02%)

82 (13.78%)

0.230

1.169

Diabetes mellitus

150 (8.29%)

7 (4.57%)

0.120

0.531

756 (17.38%)

119 (20%)

0.122

1.188

Solid organ transplant

3 (0.17%)

1 (0.65%)

0.277

3.963

8 (0.18%)

3 (0.50%)

0.137

2.750

Immunosuppression

12 (0.66%)

1 (0.65%)

1.000

0.986

48 (1.10%)

7 (1.18%)

0.835

1.067

Dementia (all causes)

0 (0%)

0 (0%)

-

-

138 (3.17%)

27 (4.54%)

0.088

1.451

Vasopressors

10 (0.55%)

1 (0.65%)

0.591

1.184

16 (0.37%)

15 (2.52%)

0.000

7.004

OR

Table 2.  Demographics and medical conditions among hospitalized patients with COVID-19 by severity.
*OR = Unadjusted odds ratio. **American Indian, Alaska Native, Asian, Black or African American, Native
Hawaiian or other Pacific Islander, Other.

We divided the patients into two age subgroups: younger (age ≥ 18 and < 50 years with 1,963 patients) and older
(≥ 50 years with 4,943 patients). The reported variables for prognosis of COVID-19 critical illness are presented
in Table 2, Supplemental Table S3, and Supplemental Table S4. For patients with age ≥ 18 and < 50 years, the variables that had statistically significant correlation with critical illness and death in patients with COVID-19 were
BMI, age, heart failure, and cardiomyopathy. For patients with age ≥ 50 years, the statistically significant variables
were BMI, age, sex, dementia, and use of vasopressors within one hour of either admission to the hospital with
COVID-19 or a first positive inpatient SARS-CoV-2 test. Vital signs values were aggregated from 24 h before to
one hour after and included (mean and standard deviation) for heart rate (HR), systolic blood pressure (SBP),
diastolic blood pressure DBP, respiratory rate (RR), blood oxygen saturation (SpO2), and body temperature.

Risk model analysis. In this paper, we trained five ML models including LR, RF, GBDT, and AdaBoost for
the all-age population (n = 6,906), and two different age subpopulations (patients with age ≥ 18 and < 50 years
with n = 1,963 and patients with age ≥ 50 years with n = 4,943) using the aggregated values of predictors. Class
distribution for outcomes show that patients with critical illness and death accounted for 7.79% of the younger
cohort with age ≥ 18 and < 50 years and 12.04% of the older cohort with age ≥ 50 years. This class imbalance
was addressed by undersampling patients with mild severity from the training set. Results were reported on
the complete test dataset, representing actual population distribution. Supplemental Table S5 represents the
performance results for three sets of developed models for younger, older patients and all-age groups. These
performance results were reported after adjusting the probability threshold to optimize models for clinical and
research applications. Among four models for the younger population, GBDT had the highest true positive rate
of 74.98%, true negative rate of 74.04%, and AUROC value of 0.78. For the older population, GBDT had a maximum true positive rate of 72.72%, true negative rate of 72.91% and AUROC of 0.81. Figure 1 represents the comparison between the AUROC values for four ML models based on the patient’s age. Relative feature importance
for the younger, older and generalized GBDT models was determined by Shapley additive explanations (SHAP),
as shown in Fig. 2, and Supplemental Fig. S5, respectively. SHAP values were also used to assess the contribution
of age on each model outcome (Supplemental Fig. S5). In addition, Supplemental Fig. S6 presents the model with
individual comorbidities as risk factors for age-stratified models. We used the distribution of importance for
each variable to assess its contribution to model outcome. In the younger population, some variables for comorbidities added no predictive value, which resulted in them being automatically removed from the SHAP plot.
Additionally, we used the GBDT to validate and assess the performance of the model for different time
horizons. For the all-age group, gradient boosting showed an AUROC value of 0.83, 0.80, 0.79 and 0.79 for
respectively, 1-, 14-, 28- and 56-day intervals after the confirmation of infection. Furthermore, we predicted
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Figure 1.  Area under receiver operator characteristic curve (AUROC) for age-stratified models of severe
COVID-19 outcomes in hospitalized patients.
the mortality of patients (WHO ordinal score of 8) using the GBDT model and the full set of aggregated risk
factors. Note that to predict the mortality of patients with COVID-19, we also included the patients who were
already receiving mechanical ventilation and additional organ support (WHO ordinal score of 6 and 7), see Supplemental Fig. S2. Therefore, the number of all age group patients for predicting mortality increased to 7,063.
The results show the AUROC value of 0.82 for the general population and 0.79 and 0.75 for the younger and
aging population, respectively.

Discussion

In this study, we developed risk models to predict the outcomes of hospitalized adult patients with COVID-19, in
the context of current COVID-19 standard of care and delta variant predominance. We used clinical data from
within one hour of either admission to the hospital with COVID-19 or the first positive inpatient SARS-CoV-2
test result. Explainability analysis on the machine learning models showed that risk factors are different for older
patients compared to younger patients. This is the first study that investigates age-stratified modeling for COVID19 severity for hospitalized adults for early prediction across multiple time horizons. Data from 6,906 patients
across five states was used to develop predictive models for COVID-19 critical illness and death in younger and
older hospitalized adults within one, seven, 14, 28 and 56 days of positive infection test and hospitalization.
The key findings are: 1) risk models perform well using readily available clinical data, 2) vital signs and laboratory results at the time of admission are more important for prediction than the presence of comorbidities, 3)
age-stratified models show that the relative importance of risk factor differs between younger and older adults.
Since the beginning of the pandemic, standard of COVID-19 care has improved and delta has become the
predominant variant. Further, risk models from earlier in the pandemic relied on labs that are not routinely used
in many patients. This was reflected by the high rate of missing values for tests required for in early risk scores,
including INR, D-dimer, ferritin and procalcitonin (PCT). The models developed here are both performant and
pragmatic.
Our statistical analysis revealed new insights on how variables that correlate significantly with critical illness
and death in COVID-19 differ between younger and older age groups. For example, most comorbidities such as
malignancy, cardiomyopathy and COPD have higher odds ratios for severe outcomes in younger patients than
in older patients. Conversely, lower BUN/creatinine ratio and lower potassium are only statistically associated
with critical illness and death in older patients.
We chose GBDT, a sequential ensemble approach30, as the model with the best relative performance to define
the most predictive variables for COVID-19 outcomes. Non-linear models showed higher performance than
linear models, suggesting better representation of complex interactions across multiple mechanisms of disease.
Stratifying patients by age group revealed that, in general, vital signs and laboratory tests have a higher relative importance than comorbidities. Because age is such a significant risk factor, it can mask other important
predictors. By removing the confounding effects of age, these models highlight new insights into risk factors
for IMV and death.
Additionally, we investigated the effect of age on predictive models for younger and older COVID-19 patients.
For patients with age ≥ 18 and < 50 years (Supplemental Fig. S5C), age has a relatively high and more consistent
predictive effect on the performance of the model. Within patients younger than 50 years old, higher age had a
negative effect on outcome. However, in patients with age ≥ 50 years (Supplemental Fig. S5D), age has less effect
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Figure 2.  Gradient Boosting Decision Tree feature importance for age-stratified models of severe COVID-19
outcomes in hospitalized patients. (A) Feature importance and the influence of higher and lower values of the
risk factors on the patient with age ≥ 18 and < 50 years outcome, (B) Feature importance and the influence of
higher and lower values of the risk factors on the patient with age ≥ 50 years outcome. Note that the left side
of this graph represents reduced risk of critical illness or death, and the right side of the graph represents the
increased risk of critical illness and death outcome. Nominal classes are binary [0, 1]. For sex, female is 0 (blue)
and for race, White is 0 (blue).
on the model performance. Patient stratification removed some of the confounding effect of age in this group,
better revealing the contribution of laboratory results, vital signs and comorbidities as predictors.
For the younger population, the patient’s initial oxygen mode and aggregated vital signs demonstrate the
highest predictive value for outcome severity. Other predictive factors include higher AST, higher creatinine, and
lower calcium levels, higher age, and higher BMI. Laboratory results have higher importance for older patients
than they do for younger patients. Features such as higher BUN, higher AST, lower HCO3, lower calcium, and
some aggregated vital signs (respiratory rate, blood pressure and S pO2) are among the most predictive. Sex is
not a strong predictive factor, despite it having an odds ratio of ~ 1.25 in both the older and younger population.
BMI is another feature that supports the importance of analyzing age subgroups separately. It is statistically
correlated to the severity of COVID-19 and is an important predictor for the younger population but shows no
significant correlation in the older population (Supplemental Fig. S4). This could be explained by higher BMI in
younger hospitalized patients compared to the older hospitalized patients with COVID-1931. Future investigation is needed to determine risks with being underweight or overweight, potentially with BMI-stratified models.
Neither race nor ethnicity had strong feature importance for prediction in the younger and older population.
This shows that although chronic comorbidities (Charlson Comorbidity Index or binary diagnostic labels),
sex, race, ethnicity may have high odds ratios in a univariate analysis, these factors are much less important in
the acute setting for predicting critical illness. Once hospitalized, biomedical observations are more predictive.
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Chronic conditions are still important for predicting the severity of COVID-19 outcomes, but medical and
clinical biomarkers have a higher predictive value. The importance of comorbidities and CCI has also been
investigated by comparing a predictive model which includes only demographics and CCI. The comparison of
models performance is presented in Supplementary Fig. S6 and SHAPs are presented in Supplementary Fig. S7
and Supplementary Fig. S8.
SHAP values also indicate the direction of variables’ impact on outcomes. For example, higher serum creatinine levels, lower platelet counts, lower lymphocyte counts, and higher neutrophil count are all predictive
of critical illness and death28 Lower calcium is associated with more severe COVID-19, as noted in previous
studies32, and this analysis shows it has higher predictive value in older patients.
Hence, age stratification shows that risk factors for severe COVID-19 differ by age, in ways that cannot be
determined in all-age models. This affirms the importance of analyzing each different age group separately,
particularly for the older population who have the greater overall risk for poor outcomes.
Also, as expected, vaccination reduced the risk of severe outcomes in the older population. Vaccination status
had relatively low importance, which may reflect the low number of hospitalized patients who had received vaccination during the observation window; only 8.10% of the younger hospitalized patients and 25.48% of older
hospitalized patients had received at least one dose of a vaccine (Supplemental Fig. S3).
Early risk stratification in patients with COVID-19 is essential to inform decisions about what level of care a
patient is likely to need. One of the main challenges of COVID-19 is the heterogeneity of presentation; therefore
factors related to poor outcomes are not always evident at admission15. In this study, ML models using readily available variables (demographics, vital signs, common laboratory test and medical history) demonstrated
strong performance for predicting the severity of COVID-19. Importantly, the population in this study included
patients from 51 hospitals and 1081 clinics across five states, using data based on the current standard of care for
COVID-19 and the delta variant. Five limitations of this retrospective study are: 1) reliance on EHR structured
data which can miss medical conditions that not diagnosed, not recorded, or noted only in free text, 2) use of
hospital reported race and ethnicity of p
 atients33 as opposed to direct per-patient measures of potential confounders (genetic information, disparities in healthcare, and individual lifetime history of beneficial and harmful
exposures, 4) use of data from within a single healthcare system. Concerns regarding generalizability of this study
are partially mitigated by the size and diversity of PSJH, which serves both urban and rural communities from
California to Alaska. Future investigations will benefit from finer granularity of subdivisions by age, BMI, and
more detailed variables on conditions and drugs that affect individual immune response.

Conclusion

We developed two age-stratified risk models for critical illness in hospitalized patients with COVID-19 and tested
them on data from patients during times of improved standard of care treatment and delta variant predominance.
For hospitalized adults, baseline data that is readily available within one hour after hospital admission or a first
positive inpatient SARS-CoV-2 test can predict critical illness within one day, and up to 56 days later. The models
for age ≥ 18 and < 50 years and the model for age ≥ 50 years were both more performant than all-age models. These
age-stratified models also revealed differences in the statistical significance and relative predictive value of risk
factors between older and younger patients, including age, BMI, vital signs, and laboratory results. In addition,
sex and chronic comorbidities had lower predictive value than vital signs and laboratory results. The results of this
age-stratified modeling approach provide advanced understanding of current risk factors for severe COVID-19
outcomes and can help inform care decisions and prioritize next steps for research.

Data availability

All clinical logic has been shared within the paper and supplemental materials. Results have been aggregated and
reported within this paper to the extent possible while maintaining privacy from personal health information
as required by law. Data are archived within Providence St Joseph Health systems in a HIPAA-secure audited
compute environment. For information, contact the Vice President of Information Management at Providence
St Joseph Health.
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